GlassScriptPhysician profile
Jori Lee Kaplan
NPI 1548654437
$5,223.17
in general payments reported to CMS, 2019-2025
33 companies · $1,680 in 2025
The $1,680 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,205 · 2021: $547 · 2022: $131 · 2023: $295 · 2024: $1,365 · 2025: $1,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,584 · Consulting Fee: $705 · Education: $50.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,583.92 |
| Consulting Fee | $705.00 |
| Education | $50.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $762.36 | 2024-2025 | Enhertu |
| Genentech USA, INC. | $569.27 | 2019 | |
| Pfizer INC. | $365.49 | 2022-2025 | |
| Genzyme Corporation | $358.95 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $349.55 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $278.88 | 2024-2025 | Imfinzi, Enhertu |
| Lilly USA, LLC | $255.07 | 2019-2025 | Inluriyo, Verzenio |
| Exelixis INC. | $240.18 | 2019-2021 | |
| Sobi, INC | $180.92 | 2024-2025 | |
| Astellas Pharma US INC | $177.10 | 2021-2024 | Padcev |
| Incyte Corporation | $165.47 | 2021-2025 | Monjuvi, Zynyz, Jakafi |
| Celgene Corporation | $149.51 | 2019-2025 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $136.59 | 2023-2025 | |
| Abbvie INC. | $136.24 | 2019-2025 | |
| Amgen INC. | $121.14 | 2025 | Kyprolis |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $118.74 | 2023-2025 | Trodelvy |
| Tactile Systems Technology INC | $116.24 | 2023 | Flexitouch Plus, Entre Plus |
| Janssen Scientific Affairs, LLC | $115.56 | 2024 | Tecvayli |
| Eisai INC. | $94.07 | 2024 | |
| Seagen INC. | $83.26 | 2019-2023 | Tukysa |
| Janssen Biotech, INC. | $66.76 | 2022-2025 | Erleada |
| Array Biopharma INC | $59.28 | 2025 | Braftovi, Mektovi, Tukysa |
| Beone Medicines USA, INC. | $54.36 | 2025 | Tevimbra |
| Merck Sharp & Dohme LLC | $48.56 | 2024-2025 | Keytruda, Lynparza |
| Stemline Therapeutics INC. | $44.10 | 2023-2025 | Orserdu |
| Taiho Oncology, INC. | $33.01 | 2024 | |
| Progenics Pharmaceuticals, INC. | $25.41 | 2024 | |
| Deciphera Pharmaceuticals INC. | $24.80 | 2025 | Qinlock, Romvimza |
| Sun Pharmaceutical Industries INC. | $24.30 | 2022 | |
| Biocon Biologics INC | $22.93 | 2025 | Yesintek |
| Emd Serono, INC. | $17.27 | 2025 | |
| Mirati Therapeutics, INC. | $16.54 | 2024 | Krazati |
| Fresenius Kabi USA, LLC | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jori Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.